Technical Analysis for SNBP - Sun Biopharma Inc.

Grade Last Price % Change Price Change
grade C 4.5 4.90% 0.2100
SNBP closed up 4.9 percent on Friday, December 6, 2019, on 25 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
See historical SNBP trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 4.90%
Narrow Range Bar Range Contraction 4.90%
Stochastic Reached Oversold Weakness 4.90%
Wide Bands Range Expansion 4.90%
Gapped Up Strength 4.90%
Oversold Stochastic Weakness 4.90%
Older signals for SNBP ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Sun BioPharma, Inc., formerly Cimarron Medical, Inc., is a clinical stage drug development company. The Company is a biopharmaceutical company focused on developing therapies for pancreatic diseases. It is engaged in the commercial development of a polyamine analogue for pancreatic cancer and for a second indication in chronic pancreatitis. The Company's products include SBP-101, SBP-102 and SBP-103. Its SBP-101 is a polyamine compound and exhibits specificity for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. It develops SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma. The SBP-102 product is in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. The SBP-103 product is in non-clinical exploratory evaluation. The Company has enrolled first patient in its Phase I clinical trial of SBP-101 in patients with previously treated pancreatic cancer.
Medicine RTT Biopharmaceutical Drug Development Pancreatic Cancer Gastroenterology Medical Emergencies Chronic Pancreatitis Pancreatic Ductal Adenocarcinoma Pancreatitis

Is SNBP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.0
52 Week Low 0.57
Average Volume 797
200-Day Moving Average 4.8941
50-Day Moving Average 3.9945
20-Day Moving Average 5.1685
10-Day Moving Average 5.3360
Average True Range 0.4984
ADX 27.45
+DI 26.1301
-DI 49.0856
Chandelier Exit (Long, 3 ATRs ) 5.5048
Chandelier Exit (Short, 3 ATRs ) 5.2452
Upper Bollinger Band 6.7526
Lower Bollinger Band 3.5844
Percent B (%b) 0.29
BandWidth 61.2982
MACD Line 0.1291
MACD Signal Line 0.3684
MACD Histogram -0.2393
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.6650
Resistance 3 (R3) 4.6467 4.5733 4.6375
Resistance 2 (R2) 4.5733 4.5313 4.5825 4.6283
Resistance 1 (R1) 4.5367 4.5054 4.5550 4.5550 4.6192
Pivot Point 4.4633 4.4633 4.4725 4.4725 4.4633
Support 1 (S1) 4.4267 4.4213 4.4450 4.4450 4.3808
Support 2 (S2) 4.3533 4.3954 4.3625 4.3717
Support 3 (S3) 4.3167 4.3533 4.3625
Support 4 (S4) 4.3350